Artificial Intelligence (AI) in Life Sciences - Market Insights, Competitive Landscape, and Market Forecast - 2034

Artificial Intelligence (AI) in Life Sciences Market Summary

• The global artificial intelligence in life sciences market is expected to increase from USD 2,240.21 million in 2025 to USD 11,521.38 million by 2034, reflecting strong and sustained growth.
• The global artificial intelligence in life sciences market is growing at a CAGR of 20.06% during the forecast period from 2026 to 2034.
• The artificial intelligence in the life sciences market is witnessing significant growth driven by a combination of key factors. The increasing demand for faster drug discovery and development is encouraging pharmaceutical and biotechnology companies to adopt AI solutions to reduce timelines and costs associated with traditional R&D processes. At the same time, the growing volume of healthcare and biological data, including genomics and real-world evidence, is creating a strong need for advanced AI tools capable of efficiently analyzing complex datasets. Additionally, the rising prevalence of chronic and complex diseases such as cancer and neurological disorders is accelerating the demand for innovative, data-driven treatment approaches. Furthermore, the increase in product development activities among key market players, including the launch of AI-based platforms and strategic collaborations, is further fueling market expansion. Collectively, these factors are driving widespread adoption of AI technologies, thereby boosting the overall growth of AI in life sciences market.
• The leading companies operating in the artificial intelligence in life sciences market include Recursion Pharmaceuticals, Insilico Medicine, Atomwise, Exscientia, BenevolentAI, NVIDIA, Medidata (Dassault Systemes), Scispot, Cyclica, Deep Genomics, Karyon Bio, Variant Bio, Intel, Advanced Micro Devices, Amazon Web Services, Microsoft, Google Cloud, IBM, Dell Technologies, CoreWeave, Illumina, Medidata, IQVIA, Accenture, Cognizant, and others.
• North America is expected to dominate the Artificial Intelligence (AI) in Life Sciences market due to the strong presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and early adoption of AI technologies. The region benefits from significant investments in research and development, growing collaborations between tech firms and life sciences companies, and high availability of healthcare data. Additionally, supportive government initiatives, well-established regulatory frameworks, and the presence of major AI solution providers further contribute to the region's market leadership.
• In the component segment of the artificial intelligence in life sciences market, the software category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of Artificial Intelligence (AI) in Life Sciences Market

• Increasing demand for faster drug discovery and development is leading to a surge in artificial intelligence in life sciences: AI significantly reduces the time and cost involved in traditional drug discovery processes. By enabling rapid target identification, molecule screening, and predictive modeling, AI helps pharmaceutical companies accelerate drug development timelines, which is especially critical in addressing urgent healthcare needs and emerging diseases.
• Growing volume of healthcare and biological data: The exponential rise in genomic, proteomic, clinical, and real-world data is driving the need for AI-based tools. AI technologies can efficiently analyze large and complex datasets, uncover hidden patterns, and generate actionable insights that are beyond human analytical capabilities.
• Increasing prevalence of chronic and complex diseases: The rising incidence of diseases such as cancer, neurological disorders, and cardiovascular conditions is driving the need for advanced diagnostic and therapeutic solutions, where AI plays a crucial role in early detection and treatment planning.

Artificial Intelligence (AI) in Life Sciences Market Report Segmentation

This artificial intelligence in life sciences market report offers a comprehensive overview of the global artificial intelligence in life sciences market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Component (Hardware, Software, and Services), Application (Drug Discovery & Development, Clinical Trials Optimization, Medical Imaging & Diagnostics, and Others), Deployment Mode (On Premises and Cloud Based), End-Users (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing artificial intelligence in life sciences market.

Artificial Intelligence (AI) in life sciences refers to the use of advanced computational technologies, such as machine learning, deep learning, and natural language processing, to analyze complex biological and healthcare data. It enables faster drug discovery, improved diagnostics, personalized treatment development, and more efficient clinical trials by identifying patterns and insights that are difficult to detect through traditional methods.

The Artificial Intelligence (AI) in the life sciences market is witnessing significant growth, driven by a combination of interrelated factors that are transforming the way research and healthcare are conducted. The increasing demand for faster drug discovery and development is a major driver, as pharmaceutical and biotechnology companies are under constant pressure to reduce the time and cost associated with traditional R&D processes. AI technologies enable rapid target identification, virtual screening of compounds, and predictive modeling, significantly accelerating drug development timelines. At the same time, the growing volume of healthcare and biological data, including genomics, proteomics, clinical data, and real-world evidence, is creating a strong need for advanced AI tools that can efficiently process and analyze vast and complex datasets to generate meaningful insights.

In addition, the rising prevalence of chronic and complex diseases such as cancer, cardiovascular disorders, and neurological conditions is increasing the demand for innovative, data-driven approaches to diagnosis and treatment. AI plays a critical role in enabling precision medicine by supporting early disease detection, risk prediction, and personalized therapy development. Furthermore, the increase in product development activities among key market players, including the launch of advanced AI-based platforms, strategic collaborations, partnerships, and investments, is accelerating innovation and expanding the scope of AI applications in life sciences. These developments are not only enhancing research capabilities but also improving clinical outcomes and operational efficiency. Collectively, these factors are driving the widespread adoption of AI technologies across the life sciences value chain, thereby significantly boosting overall market growth.

What are the latest artificial intelligence in life sciences market dynamics and trends?

The global market for artificial intelligence in life sciences has witnessed significant growth due to the increasing demand for faster drug discovery and development, and the growing volume of healthcare and biological data due to the rise in chronic and complex diseases.

The increasing demand for faster drug discovery and development has significantly boosted the adoption of Artificial Intelligence (AI) in life sciences, as traditional drug development is time-consuming (10-12 years) and highly expensive. AI enables rapid target identification, molecule generation, and predictive modeling, drastically reducing discovery timelines and improving success rates. This growing need for efficiency has pushed pharmaceutical companies to actively integrate AI platforms and collaborate with AI firms. For instance, in January 2026, a major development was the launch of a $1 billion AI co-innovation lab by NVIDIA and Eli Lilly, aimed at accelerating drug discovery through advanced AI infrastructure. Similarly, in March 2026, Insilico Medicine expanded its partnership with Eli Lilly in a deal worth up to $2.75 billion to develop AI-discovered drug candidates. Additionally, the company has continuously upgraded its Pharma.AI platform in 2026, enhancing its capabilities in generative drug design. These advancements, along with breakthroughs such as AI-designed drugs like rentosertib progressing rapidly through development stages, demonstrate how AI is transforming drug discovery into a faster, more cost-effective process.

Additionally, the growing volume of healthcare and biological data has become a major driver accelerating the adoption of Artificial Intelligence (AI) in life sciences, as traditional analytical methods are no longer sufficient to handle the scale and complexity of modern datasets. The rapid expansion of genomic sequencing, electronic health records (EHRs), clinical trial data, and real-world evidence is creating vast, diverse, and unstructured data pools that require AI-powered tools for effective interpretation and decision-making. AI enables researchers to integrate and analyze these multi-omics and clinical datasets to uncover hidden patterns, identify disease mechanisms, and accelerate drug discovery and precision medicine initiatives. For instance, in January 2026, Oracle Corporation launched the Oracle Life Sciences AI Data Platform, which unifies millions of real-world patient records and applies generative AI to extract actionable insights across research and clinical workflows. Similarly, in June 2025, Google DeepMind introduced AlphaGenome, an advanced AI system capable of analyzing large-scale DNA sequences to understand gene regulation and disease mechanisms, highlighting the increasing reliance on AI to process complex genomic data.

Thus, the factors mentioned above are expected to boost the overall market of artificial intelligence in life sciences during the forecasted period.

However, Data privacy and security concerns, along with regulatory and compliance challenges, are collectively acting as significant restraints on the growth of AI in the life sciences market. The use of sensitive patient data, including electronic health records and genomic information, raises serious concerns about data breaches, misuse, and confidentiality, making organizations cautious about adopting AI solutions. At the same time, stringent and evolving regulatory frameworks for data protection and AI-based healthcare applications create complexities in approval processes and compliance requirements. These factors increase operational costs, delay product development and commercialization, and limit data accessibility, thereby slowing the widespread adoption of AI technologies in life sciences.

Artificial Intelligence (AI) in Life Sciences Market Segment Analysis

Artificial Intelligence (AI) in Life Sciences Market by Component (Hardware, Software, and Services), Application (Drug Discovery & Development, Clinical Trials Optimization, Medical Imaging & Diagnostics, and Others), Deployment Mode (On Premises and Cloud Based), End-Users (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Artificial Intelligence (AI) in Life Sciences Market Regional Analysis

North America Artificial Intelligence (AI) in Life Sciences Market Trends

North America is expected to account for the highest proportion of 44.78% of the artificial intelligence in life sciences market in 2025, out of all regions. North America is expected to dominate the artificial intelligence in life sciences market due to the strong presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and early adoption of AI technologies. The region benefits from significant investments in research and development, growing collaborations between tech firms and life sciences companies, and high availability of healthcare data. Additionally, supportive government initiatives, well-established regulatory frameworks, and the presence of major AI solution providers further contribute to the region's market leadership.

The Artificial Intelligence (AI) in life sciences market in North America is experiencing robust growth, driven by the combined impact of increasing demand for faster drug discovery, the rapid expansion of healthcare and biological data, the rising prevalence of chronic and complex diseases, and continuous product development activities by key market players. Pharmaceutical and biotechnology companies across the region are increasingly leveraging AI to significantly reduce the time and cost associated with traditional drug development, enabling faster target identification and molecule design.

At the same time, the growing availability of large-scale datasets, including genomics, clinical records, and real-world evidence, is accelerating the adoption of AI tools capable of extracting actionable insights from complex data environments. The high burden of chronic diseases such as cancer and neurological disorders in North America further drives the need for precision medicine and advanced diagnostics, where AI plays a critical role. Additionally, strong innovation ecosystems, high R&D investments, and active collaborations are further strengthening market growth.

Recent developments highlight this momentum. For instance, in February 2026, U.S.-based Generate Biomedicines raised $400 million through its IPO to advance AI-driven protein-based drug discovery programs, while in December 2025, Excelsior Sciences secured $95 million in funding to accelerate AI-enabled small molecule drug development, significantly reducing discovery timelines. Furthermore, in 2025, the U.S. FDA approved AIM-NASH, an AI-powered tool designed to improve efficiency in liver disease clinical trials, demonstrating growing regulatory support for AI integration in drug development. The increasing number of AI-based submissions and regulatory guidance from the FDA also reflects rising adoption across the drug development lifecycle.

Collectively, these factors, supported by North America's strong technological infrastructure and favorable regulatory environment, are significantly boosting the growth of the AI in life sciences market in the region.

Europe Artificial Intelligence (AI) in Life Sciences Market Trends

The Artificial Intelligence (AI) in life sciences market in Europe is experiencing robust growth due to a strong combination of technological advancement, regulatory support, increasing data availability, and rising demand for faster and more efficient drug development. The region is rapidly emerging as a key hub for AI-driven innovation, supported by initiatives such as the European Health Data Space (EHDS) and the evolving AI regulatory framework, which are enabling secure cross-border data sharing and fostering trust in AI applications.

The growing volume of genomic, clinical, and real-world data across European countries is further accelerating the adoption of AI tools to derive actionable insights and improve research outcomes. In addition, the rising prevalence of chronic diseases such as cancer and cardiovascular disorders is driving demand for precision medicine and advanced diagnostics, where AI plays a crucial role. Europe is also witnessing strong collaboration between pharmaceutical companies, biotech firms, and AI startups, which is accelerating product development activities. For instance, in March 2026, Roche announced the launch of its AI-powered "AI factory" in collaboration with NVIDIA, integrating thousands of GPUs to accelerate drug discovery, clinical trials, and data analysis at scale. Additionally, in April 2026, Novo Nordisk partnered with OpenAI to integrate AI across its drug development pipeline, aiming to significantly enhance R&D productivity and innovation. Furthermore, Europe is witnessing increasing use of AI in clinical applications, for example, in April 2026, researchers in the UK and Ireland developed an AI-based system to predict patient response to cancer treatments, improving personalized care.

These advancements, combined with strong government support, regulatory clarity, and increasing investments, are collectively positioning Europe as a rapidly growing and competitive market for AI in life sciences.

Asia-Pacific Artificial Intelligence (AI) in Life Sciences Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the Artificial Intelligence (AI) in life sciences market, driven by rapid digital transformation, increasing investments in biotechnology, and strong government support across countries such as China, India, Japan, and South Korea. The region is witnessing a surge in the adoption of AI to accelerate drug discovery and development, optimize clinical trials, and improve patient outcomes, particularly due to the large and diverse patient population that generates vast volumes of healthcare and genomic data. Additionally, APAC has become a global hub for clinical trials, with more than half of global trials being conducted in the region, further boosting the integration of AI to enhance efficiency and reduce costs.

The increasing prevalence of chronic diseases, along with rising healthcare expenditure and expanding pharmaceutical R&D activities, is further driving demand for AI-powered solutions. Moreover, strong collaborations between global pharmaceutical companies and regional AI firms are accelerating innovation, for instance, in March 2026, a major collaboration between Eli Lilly and Insilico Medicine (with a strong APAC presence) worth up to $2.75 billion was expanded to develop AI-driven drug candidates, highlighting the region's growing role in AI-based drug discovery.

Additionally, in February 2026, the BioAsia 2026 conference held in India showcased large-scale adoption of AI across research, manufacturing, and clinical development, reflecting the region's strategic focus on AI-led innovation in life sciences. Furthermore, in November 2025, India saw the development of platforms such as Atomesus AI, aimed at democratizing access to advanced AI technologies and strengthening domestic capabilities.

These developments, combined with increasing funding, rising startup ecosystems, and the presence of major AI and biotech players, are collectively positioning APAC as the fastest-growing and most dynamic region in the AI in life sciences market.

Who are the major players in the artificial intelligence in life sciences market?

The following are the leading companies in the artificial intelligence in life sciences market. These companies collectively hold the largest market share and dictate industry trends.

• Recursion Pharmaceuticals
• Insilico Medicine
• Atomwise
• Exscientia
• BenevolentAI
• NVIDIA
• Medidata (Dassault Systemes)
• Scispot
• Cyclica
• Deep Genomics
• Karyon Bio
• Variant Bio
• Intel
• Advanced Micro Devices
• Amazon Web Services
• Microsoft
• Google Cloud
• IBM
• Dell Technologies
• CoreWeave
• Illumina
• Medidata
• IQVIA
• Accenture
• Cognizant
• Others

How is the competitive landscape shaping the artificial intelligence in life sciences market?

The competitive landscape of the Artificial Intelligence (AI) in life sciences market is highly dynamic and characterized by the presence of a mix of large technology companies, pharmaceutical giants, and innovative startups, collectively driving rapid innovation and market expansion. Major players such as IBM, IQVIA, and Oracle offer integrated, full-stack AI platforms, while pharmaceutical companies like Roche and Pfizer are increasingly embedding AI into drug discovery and development processes. At the same time, specialized AI firms such as Insilico Medicine and Atomwise focus on niche innovations, intensifying competition. In terms of market concentration, the industry is considered moderately concentrated to slightly fragmented, with the top five companies accounting for approximately 45-61% of total market share, while numerous startups continue to enter with specialized solutions. This structure reflects a balance between dominance by established players and continuous disruption by emerging companies. Additionally, high levels of strategic partnerships, mergers and acquisitions, and collaborations are shaping the market, as companies aim to expand capabilities, access data, and strengthen their competitive positioning. Overall, the competitive landscape is marked by intense innovation, moderate consolidation, and strong collaborative ecosystems, which are collectively accelerating the growth and evolution of the AI in life sciences market.

Recent Developmental Activities in the Artificial Intelligence (AI) in Life Sciences Market

• In March 2026, Insilico Medicine expanded its partnership with Eli Lilly in a deal worth up to $2.75 billion to develop AI-discovered drug candidates.
• In February 2026, Tempus AI expanded its AI-enabled clinical data platform to enhance real-world data utilization for oncology research and personalized treatment development.
• In February 2026, Isomorphic Labs introduced its advanced AI drug design engine, significantly improving protein-ligand prediction accuracy and accelerating molecule design processes.
• In January 2026, a major development was the launch of a $1 billion AI co-innovation lab by NVIDIA and Eli Lilly, aimed at accelerating drug discovery through advanced AI infrastructure.
• In January 2026, Oracle Corporation launched the Oracle Life Sciences AI Data Platform, which unifies millions of real-world patient records and applies generative AI to extract actionable insights across research and clinical workflows.

Artificial Intelligence (AI) in Life Sciences Market Segmentation

• Artificial Intelligence (AI) in Life Sciences by Component Exposure
• Software
• Hardware
• Services
• Artificial Intelligence (AI) in Life Sciences Application Exposure
• Drug Discovery & Development
• Clinical Trials Optimization
• Medical Imaging & Diagnostics
• Others
• Artificial Intelligence (AI) in Life Sciences Production Scale Exposure
• Commercial
• Clinical
• Preclinical
• Ambulance End-Users Exposure
• Pharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Others
• Artificial Intelligence (AI) in Life Sciences Geography Exposure
• North America Artificial Intelligence (AI) in Life Sciences Market
• United States Artificial Intelligence (AI) in Life Sciences Market
• Canada Artificial Intelligence (AI) in Life Sciences Market
• Mexico Artificial Intelligence (AI) in Life Sciences Market
• Europe Artificial Intelligence (AI) in Life Sciences Market
• United Kingdom Artificial Intelligence (AI) in Life Sciences Market
• Germany Artificial Intelligence (AI) in Life Sciences Market
• France Artificial Intelligence (AI) in Life Sciences Market
• Italy Artificial Intelligence (AI) in Life Sciences Market
• Spain Artificial Intelligence (AI) in Life Sciences Market
• Rest of Europe Artificial Intelligence (AI) in Life Sciences Market
• Asia-Pacific Artificial Intelligence (AI) in Life Sciences Market
• China Artificial Intelligence (AI) in Life Sciences Market
• Japan Artificial Intelligence (AI) in Life Sciences Market
• India Artificial Intelligence (AI) in Life Sciences Market
• Australia Artificial Intelligence (AI) in Life Sciences Market
• South Korea Artificial Intelligence (AI) in Life Sciences Market
• Rest of Asia-Pacific Artificial Intelligence (AI) in Life Sciences Market
• Rest of the World Artificial Intelligence (AI) in Life Sciences Market
• South America Artificial Intelligence (AI) in Life Sciences Market
• Middle East Artificial Intelligence (AI) in Life Sciences Market
• Africa Artificial Intelligence (AI) in Life Sciences Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations and applications in the life sciences are transforming the entire healthcare and research ecosystem by enabling faster, more accurate, and data-driven decision-making. AI is extensively used in drug discovery and development, where it accelerates target identification, molecule design, and prediction of drug efficacy and toxicity, significantly reducing development timelines and costs. In precision medicine, AI analyzes genomic and clinical data to develop personalized treatment strategies tailored to individual patients. AI is also revolutionizing clinical trials by optimizing patient recruitment, improving trial design, and enabling real-time monitoring through the analysis of electronic health records and real-world data. In addition, AI-powered diagnostics and medical imaging enhance early disease detection and improve accuracy in identifying conditions such as cancer and neurological disorders. Emerging applications such as virtual drug screening, digital twins (virtual patient models), and AI-driven biomarker discovery are further advancing research capabilities. Moreover, AI is enabling automation in laboratories, improving operational efficiency, and supporting decision-making through predictive analytics. Collectively, these innovations are significantly enhancing productivity, reducing costs, and improving patient outcomes, thereby driving the widespread adoption of AI in the life sciences industry.

U.S. Tariff Impact Analysis on Artificial Intelligence (AI) in Life Sciences Market:

The U.S. tariff impact on the Artificial Intelligence (AI) in life sciences market is creating a mixed but largely challenging environment, influencing both cost structures and innovation dynamics. The imposition of tariffs on imported semiconductors, medical devices, and pharmaceutical inputs is increasing the cost of AI infrastructure, including GPUs, servers, and data centers that are critical for AI-driven drug discovery and research. For instance, tariffs on advanced AI chips and semiconductor components can significantly raise the cost of AI model training and deployment, thereby limiting accessibility for smaller biotech firms and slowing innovation. At the same time, the life sciences industry is highly dependent on global supply chains, and tariffs on imports from regions such as Europe and India are disrupting supply continuity and increasing manufacturing and R&D costs.

Additionally, tariffs are impacting the availability and affordability of healthcare technologies, as a large proportion of medical devices and components used in AI applications are imported, leading to higher operational expenses for companies. However, these challenges are also pushing organizations to adopt AI more strategically-for example, using AI for supply chain optimization, scenario modeling, and cost management. Furthermore, tariffs are encouraging domestic manufacturing, reshoring strategies, and increased investments in local AI infrastructure, which may strengthen long-term market resilience in the U.S.

Overall, while U.S. tariffs act as a short-term restraint by increasing costs, supply chain disruptions, and regulatory complexity, they are simultaneously driving long-term structural changes, including local production, strategic partnerships, and increased reliance on AI-driven efficiency, thereby reshaping the growth trajectory of the AI in life sciences market.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the artificial intelligence in life sciences market report study

• Market size analysis for the current Artificial Intelligence (AI) in Life Sciences market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the artificial intelligence in life sciences market.
• Various opportunities available for the other competitors in the artificial intelligence in life sciences market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current artificial intelligence in life sciences market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the artificial intelligence in life sciences market growth in the future?

Frequently Asked Questions for the Artificial Intelligence (AI) in Life Sciences Market

1. What is the growth rate of the artificial intelligence in life sciences market?

• The artificial intelligence in life sciences market is estimated to grow at a CAGR of 20.06% during the forecast period from 2026 to 2034.

2. What is the market for artificial intelligence in life sciences?

• The global artificial intelligence in life sciences market is expected to increase from USD 2,240.21 million in 2025 to USD 11,521.38 million by 2034.

3. Which region has the highest share in the artificial intelligence in life sciences market?

• North America is expected to dominate the Artificial Intelligence (AI) in Life Sciences market due to the strong presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and early adoption of AI technologies. The region benefits from significant investments in research and development, growing collaborations between tech firms and life sciences companies, and high availability of healthcare data. Additionally, supportive government initiatives, well-established regulatory frameworks, and the presence of major AI solution providers further contribute to the region's market leadership.

4. What are the drivers for the artificial intelligence in life sciences market?

• The Artificial Intelligence (AI) in life sciences market is witnessing significant growth driven by a combination of key factors. The increasing demand for faster drug discovery and development is encouraging pharmaceutical and biotechnology companies to adopt AI solutions to reduce timelines and costs associated with traditional R&D processes. At the same time, the growing volume of healthcare and biological data, including genomics and real-world evidence, is creating a strong need for advanced AI tools capable of efficiently analyzing complex datasets. Additionally, the rising prevalence of chronic and complex diseases such as cancer and neurological disorders is accelerating the demand for innovative, data-driven treatment approaches. Furthermore, the increase in product development activities among key market players, including the launch of AI-based platforms and strategic collaborations, is further fueling market expansion. Collectively, these factors are driving widespread adoption of AI technologies, thereby boosting the overall growth of the AI in life sciences market.

5. Who are the key players operating in the artificial intelligence in life sciences market?

• Some of the key market players operating in the artificial intelligence in life sciences market include Recursion Pharmaceuticals, Insilico Medicine, Atomwise, Exscientia, BenevolentAI, NVIDIA, Medidata (Dassault Systemes), Scispot, Cyclica, Deep Genomics, Karyon Bio, Variant Bio, Intel, Advanced Micro Devices, Amazon Web Services, Microsoft, Google Cloud, IBM, Dell Technologies, CoreWeave, Illumina, Medidata, IQVIA, Accenture, Cognizant, and others.